Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management

Postgraduate Medical Journal

Volumn 88, Issue 1036, 2012, Pages 73-78

  Shah, Seema ^a   Mehta, Vivek ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BENZYDAMINE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DICLOFENAC EPOLAMINE; DIMETHYL SULFOXIDE; ESOMEPRAZOLE PLUS NAPROXEN; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PIROXICAM; PLACEBO; ROFECOXIB; VALDECOXIB;

ANALGESIA; ANKYLOSING SPONDYLITIS; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC PAIN; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FATALITY; DRUG SAFETY; DYSPEPSIA; ENTERIC COATED TABLET; ENZYME INHIBITION; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GEL; HEART INFARCTION; HEART PROTECTION; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INDIGESTION; KNEE PAIN; LIVER TOXICITY; META ANALYSIS (TOPIC); MUSCULOSKELETAL PAIN; OSTEOARTHRITIS; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOTOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SMOKING; STOMACH PROTECTION; STROKE; SYSTEMATIC REVIEW (TOPIC); TREATMENT WITHDRAWAL;

ADMINISTRATION, TOPICAL; ANALGESIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC PAIN; HUMANS; OSTEOARTHRITIS;

EID: 84856002528     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2011-130291     Document Type: Article

References (33)

1. Hyllested M, Jones S, Pederson JL, et al. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br J Anaesth 2002;88:199-214.
2. Blower A, Brooks A, Fenn G, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283-91.
3. Tramer M, Moore R, Reynolds J, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-82.
4. Office for National Statistics. 1997. http://www.statistics.gov.uk/statbase/ssdataset.asp?vlnk=6922 (accessed 25 Aug 2010).
5. Moore R, Phillips C. Cost of NSAID adverse effects to the UK National Health Service. J Med Econom 1999;2:45-55.
6. Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999;26:18-24.
7. National Centre for Health Statistics. National Vital Statistics Report. Vol. 58. 1997. http://www.cdc.gov/NCHS/data/nvsr/nvsr58/nvsr58_19.pdf (accessed 3 Sep 2010).
8. Straube S, Tramer M, Moore R, et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 2009;9:14.
9. EMEA Press release. European Medicines Agency Concludes Action on COX-2 Inhibitors. London, Uk: EMEA, 2005. Doc. Ref. EMEA/207766/2005.
10. Food and Drug Administration. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Rockville, MD: FDA, 2005.
11. Bresalier R, Sandler R, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
12. Graham D, Campen D, Hiu R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
13. Solomon S, McMurray J, Pfeffer M, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
14. Langford R, Mehta V. Selective cyclooxygenase inhibition: its role in pain and anaesthesia. Biomed Pharmacother 2006;60:323-8.
15. Bombardier C, Laine I, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
16. Dominkus M, Nicolakis M, Kotz R, et al. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittelforschung 1996;46:1138-43.
17. Lin J, Zhang W, Jones A, et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomized controlled trials. BMJ 2004;329:324.
18. Rolf C, Engstrom B, Beauchard C, et al. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (Oxford) 1999;38:564-7.
19. Heyneman C, Lawless-Liday C, Wall G. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000;60:555-74.
20. Quandt S, Chen H, Grzywacz J, et al. Use of complementary and alternative medicine by persons with arthritis: results of the National Health Interview Survey. Arthritis Rheum 2005;53:748-55.
21. Rouster-Stevens K, Nageswaran S, Arcury T, et al. How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies? BMC Complement Altern Med 2008;8:25.
22. Vaile J, Davis P. Topical NSAIDs for musculoskeletal conditions: a review of the literature. Drugs 1998;56:783-79.
23. Underwood M, Ashby D, Carnes D, et al. Topical or Oral ibuprofen for Chronic Knee Pain in Older People. The TOIB Study Executive Summary. Vol. 12. Health Technology Assessment, 2008. http://www.hta.ac.uk/pdfexecs/summ1222.pdf (accessed 15 Sep 2010).
24. Towheed T. Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2006;33:567-73.
25. Niethard F, Gold M, Solomon G, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol 2005;32:2384-92.
26. Trnavsky K, Fischer M, Vogtle-Junkert U, et al. Efficacy and Safety of 5% Ibuprofen Cream Treatment in Knee OA. Results of a Randomized, Double-Blind, Placebo-Controlled Study. J Rheumatol 2004;31:565-72.
27. Massey T, Derry S, Moore R, et al. Topical NSAIDS for acute pain in adults. Cochrane Database Syst Rev 2010;(6):CD007402. http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007402/frame.html (accessed 6 Dec 2010).
28. EMEA Press Release. European Medicines Agency Confirms Positive Benefit-risk Balance of Topical Formulations of Ketoprofen. London, UK: EMEA, 2010. Doc Ref EMA/CHMP/465633/2010.
29. National Institute for Health and Clinical Excellence. Osteoarthritis: The Care and Management of Osteoarthritis in adults. NICE clinical guideline 59. http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf (accessed 28 Aug 2010).
30. Sostek M, Fort J, Estboen L, et al. Evaluation of the long-term safety of a fixed-dose combination of naproxen and esomeprazole magnesium in patients requiring chronic nonsteroidal anti-inflammatory drug (NSAID) therapy: results from a 12-month multicenter safety study. Curr Med Res Opin 2011;27:847-54.
31. National Institute for Health and Clinical Excellence. Rheumatoid Arthritis. National Clinical Guideline for Management and Treatment in Adults. NICE clinical guideline 79. http://www.nice.org.uk/nicemedia/live/12131/43326/43326.pdf (accessed 24 Jan 2011).
32. EMEA Press Release. Cardiovascular Safety Data on Non-selective NSAIDs. EMEA. Doc Ref EMEA/410862/2006.
33. American Heart Association/American College of Cardiology Joint Scientific Statement. 2007. http://www.newsroom.heart.org/index.php?s=43&item=112 (accessed 28 Aug 2010).